摘要
背景:骨髓间充质干细胞可诱导移植免疫耐受,目前其输注方式尚无定论,临床上主要为经外周静脉全身输注,仅有少量经大鼠原肾动脉输注骨髓间充质干细胞,发现其可在肾小球内驻留,并可减轻肾小球肾炎,但无经移植肾动脉输注骨髓间充质干细胞的临床病例报道。目的:分析肾移植中经移植肾动脉输注骨髓间充质干细胞的可操作性。方法:于2009-10/12对3例慢性肾功能不全、尿毒症期患者行亲属活体供肾移植,移植过程中在移植肾动脉吻合口固定一留置针,开放移植肾血流时,经移植肾动脉以输血器加压快速输注骨髓间充质干细胞,移植过程中、移植后3个月内密切观察可能发生的并发症及移植肾功能恢复情况。结果与结论:3例患者骨髓间充质干细胞输注过程顺利,移植肾血流充盈良好,移植过程中、移植后未发生栓塞、感染、移植物抗宿主病等并发症,未发生移植肾排斥反应,移植肾功能恢复顺利。结果说明经移植肾动脉输注骨髓间充质干细胞具有临床可操作性,但异位分化、肿瘤等远期并发症尚需进一步观察。
BACKGROUND：Bone marrow mesenchymal stem cells（BMSCs） have emerged as a promising cell population for inducing immune tolerance.Currently,it is difficult to predict which route of administration is going to give the best clinical results for infusion of BMSCs in renal transplantation.Experiments in rats demonstrated that BMSCs injected into the renal artery retain in glomeruli and can reduce glomerulonephritis.No clinical experiments concerning infusion of BMSCs through transplanted renal artery were reported.OBJECTIVE：To investigate the operability of infusing BMSCs directly into the transplanted renal artery.METHODS：Three uremic patients with live donor kidney transplantation from Octobem 2009 to December 2009 were selected.During transplantation procedure,an indwelling needle was fixed at the renal artery stoma,which infusing BMSCs from transplanted renal artery directly to renal allograft when opening blood flow of transplanted kidney.Potential complications and the recovery of transplanted kidney were observed.RESULTS AND CONCLUSION：The course of the operation was smoothly,without complications,such as embolism,infection,rejection and graft-versus-host disease in three months.The results demonstrated that it is feasible to infusion BMSCs to renal transplants from transplanted renal artery,but the long-term complications,such as ectopic differentiation or tumor,need to be further confirmed.
出处
《中国组织工程研究与临床康复》
CAS
CSCD
北大核心
2010年第53期10049-10052,共4页
Journal of Clinical Rehabilitative Tissue Engineering Research
